Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Bevacizumab, Abraxane
Sponsor: Abramson Cancer Center at Penn Medicine
Collaborators: Genentech, Inc.